Drug intelligence / Profile preview

QL535

Development stage: Preclinical
Lead developer: QLSF Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

QL535 is a bispecific T-cell engager (TCE) being developed by QLSF Biotherapeutics for the treatment of prostate cancer. It is engineered using the company's proprietary TECOS (T-cell Engager with Optimized Safety) platform, which is designed to minimize the risk of cytokine release syndrome (CRS) while maintaining potent anti-tumor activity. As a bispecific antibody, QL535 simultaneously targets a tumor-associated antigen on prostate cancer cells and the CD3 complex on T cells, thereby redirecting T-cell-mediated cytotoxicity toward the tumor. The drug is currently in the IND-enabling stage of development.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on QL535.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL535.

Explore the full profile